Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2018-02-09 Major Shareholding Noti…
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-09 English
SCHEDULE 13G/A
Major Shareholding Notification
2018-02-09 English
FORM 4
Director's Dealing
2018-01-25 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-01-23 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a section titled 'Item 2.02 Results of Operations and Financial Condition,' which typically indicates a brief update on financial results but does not contain detailed financial statements or comprehensive analysis. The document length is 2959 characters, which is relatively short and consistent with a brief announcement rather than a full financial report. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The content focuses on share issuance and repurchase updates, which relate to capital structure changes. However, since the primary focus is on results of operations and financial condition without detailed financial data, and given the nature of Form 8-K filings, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-01-16 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 8, 2018. It announces preliminary unaudited financial results for 2017 and guidance for 2018, referencing a press release and a corporate slide deck attached as exhibits. The content includes a summary of financial results and a presentation at the J.P. Morgan Healthcare Conference. The document is not the full earnings release itself but a regulatory filing announcing the results and providing related materials. The length is 4844 characters, which is relatively short and consistent with an 8-K filing. Therefore, this is best classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Investor Presentation (IP).
2018-01-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.